Stockscreener 앱 받기
9.75
0.62%
0.06
시간 외 거래:
9.75
Personalis Inc 주식(PSNL)의 최신 뉴스
PSNL Q1 2026 Earnings: EPS Misses Estimates, Stock Declines on Weak ResultsRetail Earnings Report - newsline.com
Personalis (NASDAQ: PSNL) director receives 6,250 RSU award in Form 4/A update - Stock Titan
Why Personalis Stock Is Rising: Medicare Covers Lung Cancer MRD Test - Stocktwits
Lightspeed funds (NASDAQ: PSNL) report 5.8% Personalis stake after in-kind distributions - Stock Titan
Personalis Inc. (PSNL) Q1 2026 Earnings: Loss Wider Than Expected, Stock DipsPost-Announcement Reaction - newsline.com
Personalis blood collection kits receive EU regulatory approval - Investing.com UK
Personalis (PSNL) Receives CE Mark Approval for Blood Collection Kits - GuruFocus
Personalis Gains EU Approval for Blood Collection Kits Used in Genomic Testing - Moomoo
Personalis blood collection kits receive EU regulatory approval By Investing.com - Investing.com Nigeria
Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits - Business Wire
Personalis, Inc. Hits Day Low of $10.39 Amid Price Pressure - MarketsMojo
Personalis, Inc. Hits New 52-Week High of $11.84, Up 763.64% - MarketsMojo
Personalis CFO Aaron Tachibana sells $480,400 in company stock - Investing.com UK
Personalis CFO Aaron Tachibana sells $480,400 in company stock By Investing.com - Investing.com Australia
Personalis (NASDAQ: PSNL) CFO sells 40,000 shares under 10b5-1 plan - Stock Titan
Personalis Inc. (PSNL) Q1 2026 Earnings: EPS Misses Estimates Amid Revenue Reporting GapsNegative Surprise Momentum - newsline.com
Aaron L. Tachibana (PSNL) exercises 40,000 options; prior 38,799 10b5-1 sale - Stock Titan
Personalis CEO Sells 100,000 Company Shares Worth $1.1 Million. What Does That Mean for Investors? - The Globe and Mail
Personalis Inc. (PSNL) Q1 2026 Earnings: EPS Misses Estimates as Stock DeclinesEPS Estimate Trend - newsline.com
Personalis Data Highlights Early Cancer Recurrence Detection - Clinical Lab Products
Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026 - BioSpace
Assessing Personalis (PSNL) Valuation After Its Strong Recent Share Price Momentum - Yahoo Finance
Personalis Insider Sold Shares Worth $449,292, According to a Recent SEC Filing - marketscreener.com
Personalis stock hits 52-week high at $11.51 By Investing.com - Investing.com Australia
Personalis CEO Christopher M. Hall sells $1.1m in stock By Investing.com - Investing.com India
Personalis CEO Christopher M. Hall sells $1.1m in stock - Investing.com
Personalis CFO and COO Aaron Tachibana sells $449,292 in stock By Investing.com - Investing.com Australia
Personalis CFO and COO Aaron Tachibana sells $449,292 in stock - Investing.com
Personalis (NASDAQ: PSNL) CEO sells 100K shares after exercising options - Stock Titan
Personalis (PSNL) CFO sells shares via pre-set Rule 10b5-1 plan - Stock Titan
Personalis (PSNL) Is Up 34.5% After CMS Expands NeXT Personal MRD Test Medicare Coverage - simplywall.st
[144] Personalis, Inc. SEC Filing - Stock Titan
Personalis, Inc. Hits Day High with 15.7% Surge in Stock Price - MarketsMojo
Personalis: Initiating Coverage Of Cancer Testing Biotech With A Buy Rating (NASDAQ:PSNL) - Seeking Alpha
ETFs Investing in Personalis, Inc. Stocks - TradingView
Personalis gains after fourth Medicare coverage win for NeXT Personal - MSN
1.63%
2.88%
자본화:
|
볼륨(24시간):